NX-019
/ Nalo Therap
- LARVOL DELTA
Home
Next
Prev
1 to 7
Of
7
Go to page
1
March 11, 2025
A Study of NX-019 in Patients with Advanced, Epidermal Growth Factor Receptor (EGFR) Mutant Cancer
(clinicaltrials.gov)
- P1 | N=258 | Active, not recruiting | Sponsor: Nalo Therapeutics Inc. | Recruiting ➔ Active, not recruiting | Trial completion date: Oct 2027 ➔ Dec 2025 | Trial primary completion date: Feb 2027 ➔ Jun 2025
Enrollment closed • Trial completion date • Trial primary completion date • Lung Cancer • Non Small Cell Lung Cancer • Oncology • EGFR
March 25, 2024
A Study of NX-019 in Patients With Advanced, Epidermal Growth Factor Receptor (EGFR) Mutant Cancer
(clinicaltrials.gov)
- P1 | N=258 | Recruiting | Sponsor: Nalo Therapeutics Inc. | N=178 ➔ 258
Enrollment change • Metastases • Lung Cancer • Non Small Cell Lung Cancer • Oncology • EGFR
April 27, 2023
A first-in-human, open-label, dose escalation and expansion study of orally administered NX-019 in patients with advanced EGFR mutant cancer.
(ASCO 2023)
- P1 | "Part 2 will enroll patients in 5 cohorts (n = 10 or 29 each), including patients with NSCLC who have (1) new or progressing CNS metastases including leptomeningeal disease after treatment with osimertinib, (2) active CNS disease and ex20ins mutations, (3) ex20ins mutations without CNS disease and (4) other rare mutations, based on a Simon 2-stage design. The study is planned for approximately 35 centers in North America and Asia-Pacific region. Clinical trial information: NCT05514496."
Clinical • Metastases • P1 data • CNS Disorders • CNS Tumor • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • EGFR • MET • RET
December 07, 2022
NX-019 shows potency and selectivity in preclinical models of EGFR-mutant tumors
(Bioworld)
- "Researchers from Nalo Therapeutics Inc. presented the discovery and preclinical evaluation of a novel orally bioavailable and brain-penetrant epidermal growth factor receptor (EGFR) inhibitor, NX-019, being developed as a potential therapeutic agent to treat EGFR-mutant solid tumors."
Preclinical • Oncology • Solid Tumor
October 09, 2022
NX-019, a brain penetrant, mutation selective EGFR inhibitor with broad mutant EGFR activity
(ESMO Asia 2022)
- "CNS exposure studies in multiple preclinical species shows a Kp,uu of approximately 1 indicating excellent CNS exposure. Conclusions Based on the preclinical profile of broad potency and mutant selectivity for EGFR mutations with excellent CNS exposure, NX-019 is entering a Phase I dose escalation and dose expansion trial in mutant EGFR selected patients."
Dermatology • Oncology
October 14, 2022
A Study of NX-019 in Patients With Advanced, Epidermal Growth Factor Receptor (EGFR) Mutant Cancer
(clinicaltrials.gov)
- P1 | N=178 | Recruiting | Sponsor: Nalo Therapeutics Inc. | Not yet recruiting ➔ Recruiting
Enrollment open • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • EGFR
August 24, 2022
A Study of NX-019 in Patients With Advanced, Epidermal Growth Factor Receptor (EGFR) Mutant Cancer
(clinicaltrials.gov)
- P1 | N=178 | Not yet recruiting | Sponsor: Nalo Therapeutics Inc.
New P1 trial • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • EGFR
1 to 7
Of
7
Go to page
1